Press release: dupixent phase 3 study confirms significant improvements in itch and hives for patients with csu

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with csu confirming the results of cupid-a, this second pivotal study in biologic-naÏve patients met primary and key secondary endpoints, showing treatment with dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo more than 300,000 people in the us suffer from chronic spontaneous urticaria (csu) that is inadequately controlled by antihistamines data will support regulatory resubmission in the us by year-end; if approved, dupixent would be the first targeted therapy for csu in a decade paris and tarrytown, ny, september 11, 2024. a dupixent (dupilumab) confirmatory phase 3 study (liberty-cupid study c) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naÏve csu receiving background therapy with antihistamines.
REGN Ratings Summary
REGN Quant Ranking